ACE2 and COVID-19: The basis of this hypothesis is based on the fact that COVID-19 reduces the level of angiotensin-converting enzyme 2 (ACE2) in the severe disease phase (since it is exposed to proteolysis by the virus) and initiates a series of cytokine reactions with an increase in angiotensin II (AGTII) levels [6-10].